Finally, another randomized phase II/III study is evaluating the use of trastuzumab and hyaluronidase-oysk (an enzyme used in combination with pertuzumab and trastuzumab for the subcutaneous treatment of HER2-positive cancers) or a fixed dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf in combination with carboplatin–paclitaxel in patients with HER2-amplified USC or carcinosarcoma [128]. The gene discussed is ERBB2; the disease is cancer.